CD8A and COVID-19: Patients who have recovered from COVID-19 and individuals who have received a COVID-19 vaccination develop CD4+ and CD8+ T-cell immune responses specific to SARS-CoV-2, suggesting the possibility of durable T-cell immune responses [4,5].